Full Press Release Details
Corporate Presentation January 2024
Important Notices & Disclaimers This presentation (the
"Presentation") by BioAtla, Inc. ("we", "us", "our", "BioAtla", or the "Company") contains "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to statements regarding business plans and prospects and whether our clinical trials will support registration; achievement of
milestones; results, conduct, progress and timing of our research and development programs and clinical trials; expectations with respect to enrollment and dosing in our clinical trials, plans and expectations regarding future data updates, clinical
trials, regulatory meetings and regulatory submissions; plans to form collaborations or other strategic partnerships for selected assets; the potential regulatory approval path for our product candidates; expectations about the sufficiency of our
cash and cash equivalents and plans to prioritize and focus development on selected assets and indications. Words such as, but not limited to, "anticipate", "believe", "could", "estimate",
"expect", "intend", "may", "plan", "potential", "predict", "project", "should", "will", "would" or the negative of those terms,
and similar expressions that convey uncertainty of future events or outcomes, identify forward-looking statements. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates
and assumptions as of the date of this Presentation and are subject to risks and uncertainties, including those described in the Company's filings with the SEC, including but not limited to the Company's latest Quarterly Report on Form 10-Q.
Moreover, the Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for management to predict all risks, nor can the Company assess the impact of all factors on its business
or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these
forward-looking statements. The Company qualifies all the forward-looking statements in this Presentation by these cautionary statements. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or otherwise. Statements contained herein are made as of the date of this Presentation unless stated otherwise, and this Presentation shall not under any circumstances create an
implication that the information contained herein is correct as of any time after such date or that the information will be updated or revisited to reflect information that subsequently becomes available or changes occurring after that date hereof.
Certain information contained in this Presentation relates to or is based on statistical and other industry and market data obtained from independent industry publications and research, surveys and studies conducted by independent third parties as
well as the Company's own estimates of the prevalence of certain diseases and conditions. The market data used in this Presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data.
Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information.
The Company's estimates of the patient population with the potential to benefit from treatment with any product candidates the Company may develop include several key assumptions based on its industry knowledge, industry publications and
third-party research, which may be based on a small sample size and may fail to accurately reflect the addressable patient population. While the Company believes that its internal assumptions are reasonable, no independent source has verified such
assumptions. This Presentation may contain trademarks, trade names, or service marks belonging to other entities. The Company does not intend the use or display of other parties' trade names, trademarks or service marks to imply a relationship
with, or endorsement or sponsorship of, or by these other parties. None of the Company or any of its directors, officers, employees, contractors, agents, consultants, advisors or other representatives makes any representation or warranty, express or
implied, as to the accuracy or completeness of the information contained in this Presentation. BioAtla | Overview 2
BioAtla is a clinical stage company focused on transforming
cancer therapy with Conditionally Active Biologics (CABs) Two Phase 2 CAB-ADCs, Prioritized pipeline one Phase 2 CAB-CTLA-4 Proprietary technology $141.3 million in cash and Clinical readouts for and one Phase 1 dual CAB- cash equivalents as of
Broad applicability in solid multiple indications / bispecific T-cell engager 09/30/23 tumors assets through 2024 BA3011 advancing Cash position sufficient into Increases therapeutic Advancing strategic potentially registrational trial 2H 2025
collaboration window in sarcoma as well as discussions potentially in other indications BioAtla | Overview 3
Leadership Team Chief Financ ial Officer Eric Sievers, M.D. Jay Short,
Ph.D. Richard Waldron, M.B.A. Sheri Lydick Chief Medical Officer Chairman, CEO and Cofounder Chief Commercial Officer Chief Financial Officer GeneMedicine, Inc. Bin Zhang, M.D. William Boyle, Ph.D. Monica Sullivan Susie Melody Sr. VP, Clinical
Development. Sr. Research Fellow Sr. VP, Intellectual Property & Contracts Sr. VP, Human Resources CapaIP BioAtla | Overview 4
Board of Directors and Advisors Jay Short, Ph.D. Chairman, Chief
Executive Mary Ann Gray, Ph.D. Sylvia McBrinn Susan Moran, MD, MSCE Director Director Director Officer & Cofounder Director Scott Smith Lawrence Steinman, MD Eddie Williams Director Director Director Lawrence Fong, MD James Allison, Ph.D. Cancer
Immunotherapy MD Anderson Cancer Center Program, UCSF Scientific Advisor Scientific Advisor Padmanee Sharma, MD, Ph.D. Michael Manyak, MD MD Anderson Cancer Center GlaxoSmithKline Scientific Advisor Scientific Advisor BioAtla | Overview 5
Selective and targeted CAB technology widens therapeutic window, thus
has the potential to enhance clinical outcomes in multiple tumor types Acidic Cancer Cell Membrane Alkaline Healthy Cell Membrane BioAtla discovered that acidic pH at the cancer cell surface unveils binding sites that are shielded at normal pH of
healthy cells BioAtla invented CAB technology, creating antibodies that bind only to these unveiled sites on cancer cells CAB binding region is not masked or caged and thus No CAB Binding CAB Binding different from prodrugs that require irreversible
enzymatic + H + H + H cleavage to become activated + H + H + H + H + + H H CAB antibodies have the potential for increased efficacy + H with improved safety relative to traditional antibodies Chang, H.W., Frey, G., Liu, H., Xing, C., Steinman, L,
Boyle, B.J., & Short, J.M. (2021) PNAS 118(9): 1-10, Suppl. 1-19. BioAtla | Overview 6
Broad applicability of BioAtla's CAB platform across several
antibody types has the potential to treat multiple solid tumors ADCs I/O Antibodies Bispecific TCE Targets: AXL, ROR2 Target: CTLA-4 Target: EpCAM & CD3 CTLA-4 blockade activates effector Widely expressed in a variety of tumor Bispecific
antibodies bridge cancer T cells, thereby enhancing anti- types, AXL and ROR2 overexpression cells and cytotoxic T lymphocytes, tumor immunity correlates with poor prognosis, activating T cells and promoting metastasis, and drug resistance to PD-1
cancer cell lysis and EGFR therapies CAB-CTLA4 CAB-CTLA4 Tumor Cell Target CAB-Tumor Cell Target CAB-EpCAM Cytotoxic payload CAB-CD3 T Cell Target and linker BioAtla | Overview 7 ADC - antibody drug conjugate; IO - immuno-oncology; TCE
Focused Pipeline with Broad Applicability of Differentiated CAB Assets
Designed to Deliver Near-term value IND Enabling Phase 1 Phase 2 CAB Program Target Indications Pre-Clinical Clinical Clinical BA3011 UPS AXL Mecbotamab Vedotin NSCLC CAB-ADCs BA3021 Melanoma ROR2 Ozuriftamab Vedotin SCCHN Melanoma BA3071 CAB-I/O
CTLA-4 NSCLC Evalstotug Carcinomas CAB- BA3182 EpCAM x CD3 Multiple tumor types Bispecific TCE CAB Additional programs Various Multiple tumor types BioAtla | Overview 8 IND, investigational new drug; UPS, Undifferentiated Pleomorphic Sarcoma; NSCLC,
Non-small Cell Lung Cancer; SCCHN, Squamous Cell Carcinoma of the Head and Neck
I/O Antibody Platform: CTLA-4 (BA3071) - Basket Trial
CAB-CTLA4 Selectively Active in Tumor Microenvironment, thereby
Reducing Immune Related Adverse Events (irAEs) Severe irAEs Minimized irAEs Non-CAB CTLA-4 CAB CTLA-4 Normal Cell (alkaline) inhibitors Tumor selective binding anti-CTLA4 anti-CTLA4 CAB-anti-CTLA4 CAB-anti-CTLA4 Cancer cell (acidic) Cytotoxic (CD8+)
T cells T regulatory cells Normal Cell Normal Cell BioAtla | Overview 10
CAB BA3071 Effectively Reduces Clinically Relevant GI Toxicity in NHP *
Vehicle Control Nivo + IPI Nivo + Ipi 20mg/kg + 15mg/kg Positive Control GI Symptoms Nivo + CAB-BA3071 Liquid feces 20mg/kg + 15mg/kg Non-formed feces Other GI symptoms Nivo: 20mg/kg QW (~14.6mg/kg human dose) + Ipi or BA3071: 15mg/kg QW (~11mg/kg
human dose) Once weekly for four weeks exposure to Nivo + Ipi or BA3071 NHP - Nonhuman primates *Chang et al., PNAS 118 (9): 1-10, 2021 BA3071 significantly reduces GI toxicity relative to ipilimumab analog in combination with nivo BioAtla |
Combination Therapy Phase 1 BA3071 Dose Escalation ongoing (Q3W) Cycle
1 Cycle 2+ Key Objectives: Define safety profile and determine Phase 2 dose and MTD 700 mg Evaluate antitumor activity and immunogenicity (~10mg/kg) Determine PK parameters 350 mg (~5mg/kg) Key Eligibility Criteria: 210 mg CTLA-4 na ve
Treatment refractory: 70 mg melanoma non-small cell lung cancer (NSCLC) renal cell carcinoma 21 mg urothelial cancer gastric cancer 7 mg hepatocellular carcinoma (HCC) cervical cancer small cell lung cancer (SCLC) BA3071 BA3071 + 240 mg nivolumab
BioAtla | Overview 12 Further dose escalation planned to 1,000 mg
Phase 1 BA3071: Demographics - Baseline Patient Characteristics Median
of at least 3 prior lines of treatment Total (N=18) Age, y, mean (range) 65.5 (43 - 79) ECOG Status, n (%) 0 10 (55.6) 1 8 (44.4) # of prior systemic therapies, n (%) 1 5 (27.8) 2 2 (11.1) 3 4 (22.2) 4 7 (38.9) Data Cut Date: 15Nov23 BioAtla
Phase 1 BA3071: Demographics - Tumor Types All patients
experienced failure of prior PD1 treatment Total Prior Number Tumor Type Prior Treatment of Tx (N=18) pt, anti-VEGF, anti-PD1 Cervical 1 (5.6) 3 4 (22.2) 4 - 6 anti-PD1 and pt chemotherapies Gastric 1 - 2 anti-PD1 Melanoma 5 (27.8) Uveal
3 (16.7) Cutaneous 2 (11.1) 4 (22.2) 1 - 6 prior anti-PD1 and TKI Renal cell Urothelial 1 (5.6) 4 pt chemotherapies, anti-PD1 and ADC pt chemotherapies, taxanes, anti-PD1, TKI, anti-VEGF NSCLC 2 (11.1) 3 - 7 1 (5.6) 3 pt chemotherapies,
anti-PD1 SCLC Pt - Platinum; Data Cut Date: 15Nov23 BioAtla | Overview 14
Grade 3+ Adverse Events of Special Interest BA3071 Q3W + 7 mg 21 mg 70
mg 210 mg Total 350 mg 700 mg (N=7)* (N=3) nivolumab 240 mg Q3W (N=1) (N=1) (N=3) (N=3) (N=18) Number of subjects with at least one Grade 3+ AESI 0 0 2 0 1 2 5 (27.8) GI Toxicity 0 0 1 0 1 0 2 (11.1) Abdominal pain 0 0 1 0 0 0 1 (5.6) Diarrhea 0 0 0
0 1 0 1 (5.6) Liver Toxicity 0 0 2 0 0 0 2 (11.1) AST increased 0 0 1 0 0 0 1 (5.6) ALP increased 0 0 2 0 0 0 2 (11.1) Pulmonary Toxicity 0 0 0 0 0 1 1 (5.6) Pneumonia 0 0 0 0 0 1 1 (5.6) Endocrine Toxicity 0 0 0 0 0 1 1 (5.6) Diabetic ketoacidosis
0 0 0 0 0 1 1 (5.6) ^Patient with diarrhea also experienced Grade 3 gastritis * 1 Pt at 350 mg dose for Phase 2 included Red text denotes immune related AEs Data Cut Date: 15Nov23 BioAtla | Overview 15 AST - Aspartate aminotransferase; ALP -
Alkaline phosphatase
Grade 3+ Adverse Events of Special Interest BA3071 Q3W + 7 mg 21 mg 70
mg 210 mg Total 350 mg 700 mg (N=7)* (N=3) nivolumab 240 mg Q3W (N=1) (N=1) (N=3) (N=3) (N=18) Number of subjects with at least one Grade 3+ AESI 0 0 2 0 1 2 5 (27.8) GI Toxicity 0 0 1 0 1 0 2 (11.1) Abdominal pain 0 0 1 0 0 0 1 (5.6) Diarrhea 0 0 0
0 1 0 1 (5.6) Liver Toxicity 0 0 2 0 0 0 2 (11.1) Only 2 patients with immune related AEs observed among 18 treated patients AST increased 0 0 1 0 0 0 1 (5.6) ALP increased 0 0 2 0 0 0 2 (11.1) Pulmonary Toxicity 0 0 0 0 0 1 1 (5.6) Pneumonia 0 0 0
0 0 1 1 (5.6) Endocrine Toxicity 0 0 0 0 0 1 1 (5.6) Diabetic ketoacidosis 0 0 0 0 0 1 1 (5.6) ^Patient with diarrhea also experienced Grade 3 gastritis * 1 Pt at 350 mg dose for Phase 2 included Red text denotes immune related AEs Data Cut Date:
15Nov23 BioAtla | Overview 16 AST - Aspartate aminotransferase; ALP - Alkaline phosphatase
Phase 1 BA3071: Confirmed Responses (n=2) and Stable Disease (n=9)
Among 16 Evaluable Patients Uveal melanoma SCLC Cutaneous melanoma Cutaneous melanoma Gastro-esophageal (confirmed PR, 54.3% tumor reduction, post data cut) Cervical Data Cut Date: 15Nov23 BioAtla | Overview 17
Phase 1 BA3071: Meaningful Clinical Benefit at 350 mg in Combination
with PD1 Confirmed Partial and Complete Responses Uveal melanoma (PD) Uveal melanoma (SD) Overall Response to date N=5 NSCLC (PD - non-target/new lesion) Complete Response 1 Partial Response 1 Gastro-esophageal Stable Disease 1 (confirmed PR,
post data cut) Progressive Disease 2 Cervical (CR) Data Cut Date: 15Nov23 BioAtla | Overview 18
Confirmed PR - Gastro-esophageal Cancer 63-year-old male, stage IV
gastro-esophageal cancer HER2 negative, post-FOLFOX, taxane, TKI, anti-PD1 and anti-VEGFl BioAtla | Overview 19 Baseline - July 31,2023 On Treatment - October 23, 2023
Confirmed CR - Cervical Cancer 43-year-old female, stage IV cervical
cancer HPV+16 positive, post-platinum, taxane, anti-PD1 and anti-VEGF Baseline - March 23, 2023 On Treatment - August 9, 2023 "No enlarged mediastinal, hilar or axillary lymph nodes are present. There is persistent resolution
"Multiple enlarged mediastinal, paraesophageal, of previously noted enlarged mediastinal and and right hilar lymph nodes " paraesophageal lymph nodes." BioAtla | Overview 20
BA3071-001 Dose Titration Ongoing 3 patients dosed at 700 mg Q3W in
combination with nivolumab Cycles Overall Cancer Type Age Prior Tx Adverse Events DLT Disposition Completed Response G1 fever and chills; Renal cell 78 5 No 6 SD Ongoing G2 transient hypoxia DC - Subject Gastro-esophageal 66 4 G1 fever and chills No
2 SD Decision G1 fever and chills; Yes (atrial NSCLC 76 7 2 SD DC - AE G2 transient hypoxia fibrillation) Renal cell patient commenced prophylactic tocilizumab cycle 4 onward, now post 6 cycles and tolerating continued therapy
Further evaluation of 700 mg and potentially 1000 mg both with prophylactic tocilizumab BioAtla | Overview 21
BA3071 Phase 2 Mono and Combo Study Currently Underway Study designed
for multiple approval paths Treatment Refractory: Monotherapy assessment 350 mg melanoma Evaluating path for potential carcinomas accelerated approval Further characterize safety and efficacy Monotherapy and
Potential higher dose Combination with PD1 st Treatment Na ve (1 L): 350 mg melanoma NSCLC Inform path to pivotal RCT for full approval Combination with PD1 Potential higher dose BioAtla | Overview 22
CAB-AXL-ADC Platform BA3011 Mecbotamab Vedotin: Sarcoma and
Potential market opportunity in undifferentiated pleomorphic sarcoma
(UPS) newly diagnosed Targeted therapies 2nd most patients / year people in the Av Ava ail ila abl ble e T Tre rea attm me en ntt:: specifically common Soft (U.S.) - majority ~15% ~200K 0 >540K U.S. living with approved to treat Tissue
Sarcoma advanced / 1 1L: Approved treatments lung cancer 5 1,2 UPS 1L: Chemo + ICI 50% ORR (STS) subtype 2 7 metastatic for sarcoma ORR ~15% 6,7 2L+: SOC 10% - 20% ORR despite advances non-squamous patients developing Median time to in 1L care,
majority cell represents recurrent or ~55% 1 year metastatic/local 2L+ ~75% of patients majority of 4,5,6 metastatic recurrence 3 4 progress 3,4 patients disease 1 2 Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of
10,000 patients with soft tissue sarcoma. Ann Surg. 2014;260(3):416-21; Penel N, Coindre J-M, Giraud A, Terrier P, Ranchere-Vince D, Collin F, et al. Presentation and outcome of frequent and rare sarcoma histologic subtypes: a study of 10,262
patients with localized visceral/soft tissue sarcoma managed in reference 3 centers. Cancer. 2018;124(6):1179-87; Vodanovich DA, Spelman T, May D, Slavin J, Choong PFM. Predicting the prognosis of undifferentiated pleomorphic soft tissue
sarcoma: a 20-year experience of 266 4 cases. ANZ J Surg. 2019;89(9):1045-1050; Roland CL, May CD, Watson KL, et al. Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma. Ann 5 Surg Oncol.
2016;23(7):2220-2228; Delisca GO, Mesko NW, Alamanda VK, et al. MFH and high-grade undifferentiated pleomorphic sarcoma-what's in a name?. J Surg Oncol. 2015;111(2):173-177; 6 7 Winchester D, Lehman J, Tello T, et al. Undifferentiated pleomorphic
sarcoma: Factors predictive of adverse outcomes. J Am Acad Dermatol. 2018;79(5):853-859; Product USPIs BioAtla | Overview 24 ORR, objective response rate (best objective response as confirmed complete response or partial response)